Deliver Your News to the World

Januvia Pancreatic Cancer Lawsuits Moving Forward

Oral arguments have been set for July 25th, 2013 in the Januvia multidistrict litigation in front of the Judicial Panel on Multidistrict Litigation, at a hearing session, located in Portland, Maine.


WEBWIRE

Houston, TX 7/3/13 - The Januvia multidistrict litigation (MDL No. 2452) is moving forward as planned, and oral arguments will be heard on July 25th to determine if the cases should be consolidated. Houston law firm D. Miller & Associates, PLLC, continues to take these cases as the litigation progresses.

Oral arguments have been set for July 25th, 2013 in the Januvia multidistrict litigation in front of the Judicial Panel on Multidistrict Litigation, at a hearing session, located in Portland, Maine (In Re: Incretin Mimetics Products Liability Litigation MDL No. 2452).

Based on these oral arguments, the panel will determine if the cases should be consolidated for the purposes of pretrial proceedings. The incretin mimetics plaintiffs are arguing for transfer of the cases to the U.S. District Court of the Southern District of California. This multidistrict litigation surrounds a class of medications, known as incretin mimetics, which are prescribed to combat Type 2 Diabetes.

There are several different medications in this class, manufactured by several different pharmaceutical companies. The manufacturers, including Merck, Novo Nordisk, Amylin Pharmaceuticals, and Eli Lilly, have written responses to the plaintiffs’ motion to transfer vocalizing their support for consolidation and transfer of the cases to California, according to court documents. * The reasons for their support of consolidation include: (1) many plaintiffs used several of the different incretin based therapies, (2) many of the significant issues overlap and are common in the cases, (3) it would promote efficiency, and (4) it serves the convenience of the parties and witnesses in these actions.**

Consolidation of cases, like these, is generally ordered when a question of common fact exists and it would promote just and efficient treatment of the cases. It is a more efficient use of the judicial system and can expedite the process. Each plaintiff is still entitled to their own settlement, but this means is more efficient that individual filing of all of the cases. Through an MDL, all of the cases listed in it are heard by the same judge and initial trials, known as bellwhether trials, are used to determine the strength of the cases. These initial trials help to set a standard for the cases that follow, improving the efficiency.

Those who might be eligible for compensation have taken or are taking Januvia, Byetta, or Victoza and have been diagnoses with pancreatic or thyroid cancer while on the medication or shortly after.*In Re: Incretin Mimetics Products Liability Litigation MDL No. 2452** In Re: Incretin Mimetics Products Liability Litigation MDL No. 2452

About D. Miller & Associates, PLLC:Founded in 2002 by attorney Darren Miller, D. Miller & Associates, PLLC is a national law firm with practice areas in personal injury, asbestos and mesothelioma, defective drugs and devices, business and criminal law. Based in Houston, Texas, the attorneys at D. Miller & Associates, PLLC, have successfully earned their clients compensation through aggressive litigation against even the most powerful of defendants. For a free legal consultation, contact the firm at 1-855-PRO-LAWYERS  For more information, visit our website at www.dmillerlaw.com



WebWireID177116




 
 Januvia
 Byetta
 pancreatic cancer
 type 2 diabetes
 side effects


This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.